It is late on a Thursday, and a regulatory affairs specialist has a draft Investigator's Brochure due to the medical lead in the morning. The Section 5 safety summary is rough, the prose is dense, and the specialist wants it tightened. So they open a browser tab to a free, public, consumer chatbot, paste in the entire draft IB, and type "make this clearer and more concise." A clean rewrite comes back in seconds. The document reads better. And in that single paste, the specialist has just transmitted the sponsor's unpublished clinical safety data, the dosing rationale, the mechanism-of-action narrative, and the names and protocol numbers of ongoing studies to a third-party system over which the sponsor has no contractual control, no data-retention guarantee, and quite possibly an agreement that permits the provider to use submitted content to improve its models. The rewrite was free. The exposure was not. This lesson is about the three categories of information that walk out the door when regulated content meets an ungoverned tool, and about the operational floor, the vendor Business Associate Agreement plus zero data retention, that separates a defensible enterprise tool from a confidentiality incident.

What Actually Happens When You Paste Into a Public Model

The mental error behind the IB paste is treating a public chatbot like a private utility, a smarter word processor that happens to live in a browser. It is not. When you submit text to a consumer AI service, that text leaves your organization's control and enters the provider's infrastructure, where what happens next is governed entirely by that provider's terms of service and data-handling policy, not by your intentions. In the default configuration of many consumer tools, submitted content may be retained, may be reviewed by humans for quality and safety, and may be used to train or improve future models. None of those outcomes is visible to you, and none is reversible once the text has been sent.

This is the difference between a tool you operate and a tool you merely use. A word processor on your validated laptop keeps the document inside your environment. A public model takes the document out of it. The data does not come back when you close the tab; it has already been transmitted, and the question of who can see it, how long it is kept, and whether it trains the next model version is now answered by someone else's policy. For ordinary personal text this is a low-stakes trade. For a sponsor's unpublished regulatory content it is a confidentiality breach the moment the paste completes, regardless of whether anyone ever misuses the data, because the obligation the sponsor owes is to control the information, and control was surrendered at the paste.

The reason this is easy to do and hard to see is that nothing alarming happens on screen. The interface is friendly, the rewrite is helpful, and there is no warning that the input was just absorbed into an external system. The harm is invisible at the moment it occurs and becomes visible only later, in a partner audit, a due-diligence review, or a competitor's suspiciously well-informed filing. The discipline this lesson builds is to recognize the categories of information that must never cross that boundary, and to know what a properly governed tool provides instead.

PHI: Protected Health Information in Case Narratives

The first category is Protected Health Information, PHI, the patient-identifiable health data governed under HIPAA in the United States and under equivalent data-protection regimes elsewhere. PHI is pervasive in pharmacovigilance, because the raw material of a safety case is a real person's medical story. An individual case safety report, an ICSR, and the case narrative built from it can contain a patient's age, sex, geographic location, dates of treatment, comorbidities, concomitant medications, and a free-text account of the adverse event, and in combination these elements can identify an individual even when an explicit name is absent.

When a pharmacovigilance associate pastes an unredacted case narrative into a public model to "clean up the language," they are exposing PHI to an external system, which is both a confidentiality failure and a potential regulatory breach under HIPAA and the data-protection law of the patient's jurisdiction. The fact that the goal was benign, better prose, does not change the exposure, because PHI does not become less protected when the intent is editorial. The narrative is built from a real patient's data, and that data is owed protection regardless of what the associate meant to do with it.

The governed alternative is not "avoid AI for narratives." It is to use a tool that contractually handles PHI, which in the United States means a vendor operating under a Business Associate Agreement, the BAA, the contract HIPAA requires whenever a service provider handles PHI on a covered entity's behalf. A vendor under a BAA has accepted legal obligations for how it stores, secures, and disposes of PHI; a consumer chatbot with no BAA has accepted none. The single most important question a PV associate can ask before pasting a narrative is not "will this improve the text" but "is this tool covered by a BAA," because the answer decides whether the workflow is defensible or a breach.

CCI: Commercial Confidential Information in Form 483 Responses

The second category is Commercial Confidential Information, CCI, the business-sensitive information whose disclosure would harm the sponsor's competitive position, and it concentrates in places that do not look like trade secrets at first glance. A Form 483, the list of inspectional observations an FDA investigator issues at the close of an inspection, prompts a written response from the firm, and that response routinely contains CCI: the specifics of manufacturing processes, the details of a quality system's failures and the corrective actions planned, the internal investigation findings, and the commercial context of a facility's operations. A 483 response is a candid internal account of what went wrong and how the firm will fix it, which is exactly the kind of information a competitor or an adversary would value.

Pasting a draft 483 response into a public model to strengthen the argument or smooth the tone exposes that candid account, including the firm's self-identified deficiencies and remediation strategy, to an external system. The damage here is competitive and reputational rather than patient-facing, but it is real: a firm's frank admission of a manufacturing problem and its remediation plan is information it controls precisely because disclosure would be costly, and that control evaporates the moment the draft enters an ungoverned tool. CCI also appears in regulatory correspondence, in meeting briefing documents, and in the commercial sections of submissions, and the same rule governs all of them.

The governed posture for CCI mirrors the one for PHI: the content may only be handled in a tool whose contract gives the sponsor control over the data, with no retention and no training use, because CCI loses its value the instant it leaks. The distinction that matters is not whether the AI is helpful but whether the information stays inside a boundary the sponsor controls. A 483 response drafted with an enterprise tool under the right contractual terms is a legitimate, accelerated workflow; the same draft pasted into a consumer tool is a disclosure of confidential business information the sponsor cannot retract.

Trade Secrets in CMC Sections

The third category is the trade secret, and it lives most densely in Module 3, the Chemistry, Manufacturing, and Controls content of a submission. CMC sections contain a manufacturer's most closely guarded technical knowledge: the synthetic route for a drug substance, the formulation and process parameters for a drug product, the analytical methods, the in-process controls, and the manufacturing know-how that took years and substantial investment to develop. Much of this qualifies as trade secret, information that derives its commercial value precisely from not being generally known and that the firm protects through deliberate secrecy.

A trade secret has a legal property the other categories do not share quite so starkly: its protected status can depend on the holder having taken reasonable measures to keep it secret. Pasting a Module 3.2.S drug substance section or a process description into a public model is not only a competitive exposure; it can undermine the legal claim that the information is a trade secret at all, because voluntary disclosure to an uncontrolled third-party system is the opposite of reasonable measures to maintain secrecy. The harm is therefore doubled: the information may be exposed, and the legal protection that would let the firm act against misuse may be weakened by the disclosure itself.

This is why CMC content is among the most sensitive material a regulated AI workflow can touch, and why the governance bar for it is the highest. A medical writer or CMC specialist drafting Module 3 with AI assistance must use a tool whose data handling preserves the secrecy on which the trade secret's protection rests, which again means an enterprise deployment with contractual control, no retention, and no training use. The convenience of a public model is never worth the compounded loss of a competitive position and the legal standing to defend it.

The BAA Plus Zero Data Retention Operational Floor

Across all three categories, the same two contractual mechanisms define the floor below which a regulated AI workflow is not defensible. The first is the Business Associate Agreement, the BAA, which is mandatory in the United States whenever a tool will handle PHI and which binds the vendor to specific legal obligations for safeguarding that data. The second is zero data retention, ZDR, a configuration in which the provider does not store the content you submit beyond the moment it is processed and, critically, does not use it to train or improve models. ZDR is what turns "the data left my environment" into "the data was processed and then immediately discarded, never retained, never used for training."

The combination, a vendor BAA where PHI is involved plus a zero-data-retention guarantee for all sensitive content, is the operational floor for handling PHI, CCI, and trade secrets in an AI tool. It is the floor, not the ceiling: a full enterprise deployment also brings audit trails, access controls, validation, and the Part 11 and Annex 11 controls covered elsewhere in this program. But BAA plus ZDR is the minimum that distinguishes a tool you can defensibly put regulated content into from one you cannot. The practical test for any specialist is concrete: before pasting sensitive content, confirm that the tool is the organization's governed enterprise deployment, that a BAA is in place where PHI applies, and that data retention and training use are contractually disabled. If you cannot confirm those, the content does not go in.

This is also the bright line between governed enterprise tools and consumer tools, and the line is not about the quality of the model. The same underlying model can sit behind a consumer chatbot with retention-on, training-on defaults and behind an enterprise deployment with a BAA and ZDR, and the difference between them is entirely contractual and configurational, not a difference in how good the rewrite is. The free tool may even produce a better paragraph. It is still the wrong tool for an Investigator's Brochure, because the question that governs regulated content is never "which tool writes best" but "which tool lets me keep control of information I am obligated to protect." The governed tool is the one that keeps the IB, the case narrative, the 483 response, and the CMC section inside a boundary the sponsor controls. That boundary is the whole point.

The Three Categories Rarely Arrive Alone

One reason the confidentiality judgment is harder than it looks is that a single regulated document frequently carries more than one category at once, so the specialist who screens only for the obvious one still leaks the others. A clinical study report excerpt can contain PHI in its case narratives, CCI in its commercial and operational context, and trade-secret material in its analytical and manufacturing references, all in the same file. An Investigator's Brochure carries unpublished safety data that is competitively sensitive, dosing and mechanism content that approaches trade secret, and study identifiers that can connect to patient-level data. The opening specialist who thought only about whether the IB was "confidential" missed that it was confidential in three distinct legal senses at once, each with its own consequence.

This compounding matters because the controls differ slightly by category but the failure is shared: one paste exposes whatever is in the document, indiscriminately. A tool that is acceptable for one category is not automatically acceptable for the document as a whole if the document also carries a category the tool does not adequately handle. A vendor that offers a BAA satisfies the PHI requirement, but if it cannot also guarantee zero retention and no training use, it does not satisfy the trade-secret requirement, and a CMC-bearing document needs both. The safe rule treats the most demanding category present as the one that governs, which for regulated content almost always means requiring the full floor of a governed enterprise deployment with a BAA and ZDR, because partial coverage of a multi-category document is functionally no coverage at all.

The practical consequence is that the specialist should not try to perform a fine-grained legal triage of every sentence under deadline pressure, which is error-prone and slow. The reliable move is the coarse one: treat any regulated document as carrying sensitive content unless proven otherwise, and route the whole document to the governed tool. This is faster than per-sentence classification and far safer, because it removes the judgment that fails, the moment when a tired specialist decides a particular paragraph is "probably fine" and pastes it into a consumer tool. There is no upside to that decision that justifies the downside, and the coarse rule eliminates the decision entirely.

Building the Reflex Before the Paste

The failure in the opening scene was not a lack of knowledge; the specialist almost certainly knew the IB was confidential. The failure was that the confidentiality judgment never fired at the moment of the paste, because the tool felt like a utility and the task felt routine. The defense, therefore, is not more policy documents but a reflex that triggers before the content leaves the environment, a habit of classifying the input before submitting it. The classification is fast: does this text contain PHI, CCI, or trade secret material? For regulated content the answer is almost always yes, because an IB, a case narrative, a 483 response, and a Module 3 section each carry at least one of the three.

Once the reflex fires, the rule is simple and absolute: sensitive content goes only into the governed enterprise tool, never into a consumer one, full stop. There is no version of "just this once" or "it is only a small section" that survives scrutiny, because a partial paste of a CMC section is still a trade-secret disclosure and a single case narrative still carries PHI. The specialist who internalizes this does not lose the speed AI offers; they simply route the work to the tool that was built to receive it. The governed tool drafts the IB summary, tightens the 483 response, and cleans the narrative just as capably, while keeping every category of protected information inside the contractual boundary the sponsor controls. The reflex, classify before you paste, is the entire difference between an accelerated workflow and an incident report, and it costs nothing but the half-second of attention the opening specialist did not spend.

Key Takeaways

• Pasting regulated content into a public consumer model is a confidentiality breach the moment the paste completes, regardless of intent or whether anyone misuses the data, because submitted content leaves the sponsor's control and is governed by the provider's terms, which may permit retention, human review, and training use.
• PHI in case narratives is protected health information owed protection under HIPAA and equivalent regimes, and the deciding question before pasting a narrative is whether the tool operates under a Business Associate Agreement (BAA), not whether the rewrite improves the prose.
• CCI in Form 483 responses is candid business-sensitive information, the firm's self-identified deficiencies and remediation plans, that loses its value the instant it leaks; it also appears in regulatory correspondence and the commercial sections of submissions, and must stay inside a sponsor-controlled boundary.
• Trade secrets in CMC (Module 3) sections carry a doubled risk: voluntary disclosure to an uncontrolled tool exposes the synthetic route, process parameters, and analytical methods, and can undermine the legal claim that the information is a trade secret, because secrecy depends on reasonable measures to keep it secret.
• The operational floor is a vendor BAA (where PHI applies) plus zero data retention (ZDR), no storage and no training use. The line between governed enterprise tools and consumer tools is contractual and configurational, not a difference in model quality; classify the input before you paste, and sensitive content goes only into the governed tool.